27706165|t|Leprosy Drug Resistance Surveillance in Colombia: The Experience of a Sentinel Country
27706165|a|An active search for Mycobacterium leprae drug resistance was carried out, 243 multibacillary patients from endemic regions of Colombia were included from 2004 to 2013 in a surveillance program. This program was a World Health Organization initiative for drug resistance surveillance in leprosy, where Colombia is a sentinel country. M. leprae DNA from slit skin smear and/or skin biopsy samples was amplified and sequenced to identify mutations in the drug resistance determining region (DRDR) in rpoB, folP1, gyrA, and gyrB, the genes responsible for rifampicin, dapsone and ofloxacin drug-resistance, respectively. Three isolates exhibited mutations in the DRDR rpoB gene (Asp441Tyr, Ser456Leu, Ser458Met), two in the DRDR folP1 gene (Thr53Ala, Pro55Leu), and one isolate exhibited mutations in both DRDR rpoB (Ser456Met) and DRDR folP1 (Pro55Leu), suggesting multidrug resistance. One isolate had a double mutation in folP1 (Thr53Ala and Thr88Pro). Also, we detected mutations outside of DRDR that required in vivo evaluation of their association or not with drug resistance: rpoB Arg505Trp, folP1 Asp91His, Arg94Trp, and Thr88Pro, and gyrA Ala107Leu. Seventy percent of M. leprae mutations were related to drug resistance and were isolated from relapsed patients; the likelihood of relapse was significantly associated with the presence of confirmed resistance mutations (OR range 20.1-88.7, p < 0.05). Five of these relapsed patients received dapsone monotherapy as a primary treatment. In summary, the current study calls attention to M. leprae resistance in Colombia, especially the significant association between confirmed resistance mutations and relapse in leprosy patients. A high frequency of DRDR mutations for rifampicin was seen in a region where dapsone monotherapy was used extensively.
27706165	0	7	Leprosy	T038	UMLS:C0023343
27706165	8	23	Drug Resistance	T038	UMLS:C0013203
27706165	24	36	Surveillance	T058	UMLS:C0733511
27706165	40	48	Colombia	T082	UMLS:C3245499
27706165	54	64	Experience	T038	UMLS:C0596545
27706165	70	86	Sentinel Country	T082	UMLS:C0454664
27706165	90	103	active search	T062	UMLS:C4290001
27706165	108	128	Mycobacterium leprae	T007	UMLS:C0026922
27706165	129	144	drug resistance	T038	UMLS:C0013203
27706165	166	180	multibacillary	T038	UMLS:C1562585
27706165	195	210	endemic regions	T082	UMLS:C0017446
27706165	214	222	Colombia	T082	UMLS:C3245499
27706165	214	222	Colombia	T082	UMLS:C3245499
27706165	260	280	surveillance program	T062	UMLS:C1515095
27706165	287	294	program	T062	UMLS:C1515095
27706165	301	326	World Health Organization	T092	UMLS:C0043237
27706165	342	357	drug resistance	T038	UMLS:C0013203
27706165	358	370	surveillance	T058	UMLS:C0733511
27706165	374	381	leprosy	T038	UMLS:C0023343
27706165	389	397	Colombia	T082	UMLS:C3245499
27706165	403	419	sentinel country	T082	UMLS:C0454664
27706165	421	430	M. leprae	T007	UMLS:C0026922
27706165	431	434	DNA	T103	UMLS:C0012854
27706165	440	455	slit skin smear	T017	UMLS:C0444101
27706165	463	482	skin biopsy samples	T017	UMLS:C0586537
27706165	487	496	amplified	T038	UMLS:C0683230
27706165	501	510	sequenced	T058	UMLS:C0917792
27706165	523	532	mutations	T038	UMLS:C0596611
27706165	540	574	drug resistance determining region	T017	UMLS:C0017337
27706165	576	580	DRDR	T017	UMLS:C0017337
27706165	618	623	genes	T017	UMLS:C0017337
27706165	640	650	rifampicin	T103	UMLS:C0035608
27706165	652	659	dapsone	T103	UMLS:C0010980
27706165	664	673	ofloxacin	T103	UMLS:C0028902
27706165	674	689	drug-resistance	T038	UMLS:C0013203
27706165	711	719	isolates	T103	UMLS:C1764827
27706165	730	739	mutations	T038	UMLS:C0596611
27706165	747	751	DRDR	T017	UMLS:C0017337
27706165	763	772	Asp441Tyr	T038	UMLS:C0596611
27706165	774	783	Ser456Leu	T038	UMLS:C0596611
27706165	785	794	Ser458Met	T038	UMLS:C0596611
27706165	808	812	DRDR	T017	UMLS:C0017337
27706165	825	833	Thr53Ala	T038	UMLS:C0596611
27706165	835	843	Pro55Leu	T038	UMLS:C0596611
27706165	854	861	isolate	T103	UMLS:C1764827
27706165	872	881	mutations	T038	UMLS:C0596611
27706165	890	894	DRDR	T017	UMLS:C0017337
27706165	901	910	Ser456Met	T038	UMLS:C0596611
27706165	916	920	DRDR	T017	UMLS:C0017337
27706165	928	936	Pro55Leu	T038	UMLS:C0596611
27706165	976	983	isolate	T103	UMLS:C1764827
27706165	997	1005	mutation	T038	UMLS:C0596611
27706165	1016	1024	Thr53Ala	T038	UMLS:C0596611
27706165	1029	1037	Thr88Pro	T038	UMLS:C0596611
27706165	1049	1057	detected	T033	UMLS:C0442726
27706165	1058	1067	mutations	T038	UMLS:C0596611
27706165	1079	1083	DRDR	T017	UMLS:C0017337
27706165	1098	1105	in vivo	T082	UMLS:C1515655
27706165	1106	1116	evaluation	T058	UMLS:C0220825
27706165	1150	1165	drug resistance	T038	UMLS:C0013203
27706165	1172	1181	Arg505Trp	T038	UMLS:C0596611
27706165	1189	1197	Asp91His	T038	UMLS:C0596611
27706165	1199	1207	Arg94Trp	T038	UMLS:C0596611
27706165	1213	1221	Thr88Pro	T038	UMLS:C0596611
27706165	1232	1241	Ala107Leu	T038	UMLS:C0596611
27706165	1262	1271	M. leprae	T007	UMLS:C0026922
27706165	1272	1281	mutations	T038	UMLS:C0596611
27706165	1298	1313	drug resistance	T038	UMLS:C0013203
27706165	1442	1452	resistance	T038	UMLS:C0013203
27706165	1453	1462	mutations	T038	UMLS:C0596611
27706165	1536	1543	dapsone	T103	UMLS:C0010980
27706165	1544	1555	monotherapy	T058	UMLS:C0087111
27706165	1569	1578	treatment	T058	UMLS:C0087111
27706165	1604	1609	study	T062	UMLS:C2603343
27706165	1629	1638	M. leprae	T007	UMLS:C0026922
27706165	1639	1649	resistance	T038	UMLS:C0013203
27706165	1653	1661	Colombia	T082	UMLS:C3245499
27706165	1720	1730	resistance	T038	UMLS:C0013203
27706165	1731	1740	mutations	T038	UMLS:C0596611
27706165	1756	1763	leprosy	T038	UMLS:C0023343
27706165	1794	1798	DRDR	T017	UMLS:C0017337
27706165	1799	1808	mutations	T038	UMLS:C0596611
27706165	1813	1823	rifampicin	T103	UMLS:C0035608
27706165	1838	1844	region	T082	UMLS:C0017446
27706165	1851	1858	dapsone	T103	UMLS:C0010980
27706165	1859	1870	monotherapy	T058	UMLS:C0087111